(Reuters) – Amgen Inc and Novartis said late on Wednesday that episodic migraine sufferers reported fewer debilitating headaches per month after using the companies' investigational drug erenumab, compared to trial participants who got a placebo. The companies are racing rivals including Eli Lilly, Alder Biopharmaceuticals, Allergan and Teva Pharmaceuticals to have a new, more effective migraine treatment approved by U.S. and European regulators. Novartis anticipates filing for approval of erenumab, also known as AMG 334, next year, and will now discuss the latest data will regulators, it said.
View original post here:
Amgen, Novartis aim for big, crowded migraine market after new drug data
